Cav1.2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cav1.2 (encoded by CACNA1C) is the primary L-type voltage-gated calcium channel in neurons and cardiac myocytes. It couples electrical activity to biochemical signaling and plays essential roles in synaptic plasticity, gene transcription, and cellular excitability.
Cav1.2 has the characteristic structure of high voltage-activated calcium channels:
- Primary Structure: Single polypeptide of ~2,000 amino acids
- Domain Organization: Four homologous domains (I-IV), each containing 6 transmembrane segments
- Key Regions:
- Voltage sensor: S4 segments with positively charged residues
- Dihydropyridine binding site: Between domains III and IV
- CaM binding domain: IQ motif in C-terminus
- Auxiliary Subunits: α2δ, β, γ subunits modulate function
Cav1.2 mediates L-type calcium currents with distinct properties:
- Synaptic Plasticity: Couples synaptic activity to CREB-mediated gene transcription
- Dendritic Function: Regulates calcium in dendritic spines during LTP/LTD
- Gene Expression: Activates calcium-dependent transcription factors
- neuronal Development: Critical for dendritic growth and synapse formation
- Causative mutations (e.g., G406R) cause gain-of-function
- Prolonged channel opening leads to arrhythmias and autism
- Severe neurodevelopmental phenotype
- GWAS associations with bipolar disorder, schizophrenia, major depression
- Risk variants affect channel expression and splicing
- May disrupt calcium signaling in cortical neurons
- Dysregulated Cav1.2 contributes to calcium homeostasis failure
- Amyloid-beta affects channel function
- Target for calcium dysregulation correction
- Protects dopaminergic neurons through regulated calcium influx
- L-type blockers show neuroprotective potential
| Drug/Agent |
Mechanism |
Status |
| Nimodipine |
Dihydropyridine antagonist |
Approved (CNS penetrant) |
| Amlodipine |
Dihydropyridine antagonist |
Approved (hypertension) |
| Diltiazem |
Benzothiazepine antagonist |
Approved |
| Verapamil |
Phenylalkylamine antagonist |
Approved |
| Bay K8644 |
Agonist |
Research use |
- Striessnig J, et al. (2010). L-type Ca2+ channel diseases. J Mol Neurosci.
- Zamponi GW, et al. (2015). Calcium channel signaling. Nat Rev Neurosci.
- Moosmang S, et al. (2005). Role of Cav1.2 in neuronal function. Brain Res Rev.
The study of Cav1.2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.